Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings-A blinded comparison of commercially available vaccines

Vaccine

Volumn 31, Issue 45, 2013, Pages 5216-5222

  Gildea, Sarah ^a   Quinlivan, Michelle ^a   Murphy, Barbara A ^b   Cullinane, Ann ^a  

^a IRISH EQUINE CENTRE   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antibody; Cell mediated immunity; Comparison; Equine influenza; Thoroughbred; Vaccine

Indexed keywords

CYTOKINE; DUVAXYN IE T PLUS; EQUALIS PREQUENZA TE; GAMMA INTERFERON; HUMORAL ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 4; ISCOM; PROTEQFLU TE; RECOMBINANT CANARYPOX VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WEST NILE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION; HORSE; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; VACCINATION;

ANTIBODY; CELL MEDIATED IMMUNITY; COMPARISON; EQUINE INFLUENZA; THOROUGHBRED; VACCINE;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; GENE EXPRESSION PROFILING; HORSE DISEASES; HORSES; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84885953075     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.083     Document Type: Article

References (53)

1. Webster R.G. Are equine 1 influenza viruses still present in horses?. Equine Vet J 1993, 25:537-538.
2. OIE Bulletin. OIE Expert surveillance panel of equine influenza vaccines-conclusions and recommendations. Mill Hill, London (United Kingdom) 18th January, 2008 (2) 42-5.
3. Cullinane A. Equine influenza - a constantly evolving challenge. Equine Vet Educ 2009, 8:1-7.
4. Guthrie A.J., Stevens K.B., Bosman P.P. The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Rev Sci Tech 1999, 18(1):179-185.
5. King E.L., Macdonald D. Report of the Board of Inquiry appointed by the Board of the National Horseracing Authority to conduct enquiry into the causes of the equine influenza which started in the Western cape in early December 2003 and spread to the Eastern Cape and Gauteng. Aust Equine Vet 2004, 23:139-142.
6. Uppal P.K., Yadav M.P., Oberoi M.S. Isolation of A/Equi-2 virus during 1987 equine influenza epidemic in India. Equine Vet J 1989, 21(5):364-366.
7. Powell D.G., Watkins K.L., Li P.H., Shortridge K.F. Outbreak of equine influenza among horses in Hong Kong during. Vet Rec 1995, 136(21):531-536.
8. Garner M.G., Cowled B., East I.J., Moloney B.J., Kung N. Evaluating the effectiveness of the response to equine influenza in the Australian outbreak and the potential role of early vaccination. Aust Vet J 2011, 89(Suppl. 1):143-145.
9. Mumford J.A., Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand 1992, 79:137-146.
10. Mumford J.A., Jessett D., Dunleavy U., Wood J., Hannant D., Sundquist B., et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994, 12(9):857-863.
11. Newton J.R., Townsend H.G., Wood J.L., Sinclair R., Hannant D., Mumford J.A. Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J 2000, 32(1):65-74.
12. Mumford J.A. Biology epidemiology and vaccinology of equine influenza. Quality control of equine influenza vaccines. Proceedings of an International Symposium organised by the European Directorate for the Quality of Medicines (EDQM) 2001, 7-12.
13. Gildea S., Arkins S., Walsh C., Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings-a randomised blind study. Vaccine 2011, 29(49):9214-9223.
14. Townsend H.G., Penner S.J., Watts T.C., Cook A., Bogdan J., Haines D.M., et al. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J 2001, 33(7):637-643.
15. Hannant D., Mumford J.A., Jessett D.M. Duration of circulating antibody and immunity following infection with equine influenza virus. Vet Rec 1988, 122(6):125-128.
16. Bryant N.A., Paillot R., Rash A.S., Medcalf E., Montesso F., Ross J., et al. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak. Vet Res 2010, 41(2):19.
17. Paillot R., Kydd J.H., MacRae S., Minke J.M., Hannant D., Daly J.M. New assays to measure equine influenza virus-specific Type 1 immunity in horses. Vaccine 2007, 25(42):7385-7398. 16.
18. Adams A.A., Sturgill T.L., Breathnach C.C., Chambers T.M., Siger L., Minke J.M., et al. Humoral and cell-mediated immune responses of old horses following recombinant canarypox virus vaccination and subsequent challenge infection. Vet Immunol Immunopathol 2011, 139(2-4):128-140.
19. Paillot R., Grimmett H., Elton D., Daly J.M. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 2008, 39(3):21.
20. Paillot R., Prowse L. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse. Vet Immunol Immunopathol 2012, 145(1-2):516-521.
21. Paillot R., Prowse L., Montesso F., Huang C.M., Barnes H., Escala J. Whole inactivated equine influenza vaccine: efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity. Vet Microbiol 2013, 162(2-4):396-407.
22. Stordeur P., Zhou L., Byl B., Brohet F., Burny W., de Groote D., et al. Immune monitoring in whole blood using real-time PCR. J Immunol Methods 2003, 276(1-2):69-77.
23. Breathnach C.C., Rudersdorf R., Lunn D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004, 98(3-4):127-136.
24. Shebl F.M., Pinto L.A., Garcia-Pineres A., Lempicki R., Williams M., Harro C., et al. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev 2010, 19(4):978-981.
25. Quinlivan M., Nelly M., Prendergast M., Breathnach C., Horohov D., Arkins S., et al. Pro-inflammatory and antiviral cytokine expression in vaccinated and unvaccinated horses exposed to equine influenza virus. Vaccine 2007, 25(41):7056-7064. 10.
26. Soboll Hussey G., Hussey S.B., Wagner B., Horohov D.W., Van de Walle G.R., Osterrieder N., et al. Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant. Vet Res 2011, 42(1):23.
27. Montgomery J.B., Wichtel J.J., Wichtel M.G., McNiven M.A., McClure J.T., Markham F., et al. Effects of selenium source on measures of selenium status and immune function in horses. Can J Vet Res 2012, 76(4):281-291.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
29. Heldens J.G., Weststrate M.W., van den Hoven R. Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines-a retrospective analysis of three independent field trials. J Immunol Methods 2002, 264(1-2):11-17. 1.
30. Heldens J.G., Van de Wouw J.C., Van Loon A.A. An updated equine influenza vaccine and an equine influenza-herpesvirus combination vaccine containing an immunostim adjuvant provoke equal antibody levels in young foals throughout the primary vaccination course. Vet J 2002, 164(3):288-291.
31. Cullinane A., Weld J., Osborne M., Nelly M., McBride C., Walsh C. Field studies on equine influenza vaccination regimes in thoroughbred foals and yearlings. Vet J 2001, 161(2):174-185.
32. Daly J.M., Sindle T., Tearle J., Barquero N., Newton J.R., Corning S. Equine influenza vaccine containing older H3N8 strains offers protection against A/eq/South Africa/4/03 (H3N8) strain in a short-term vaccine efficacy study. Equine Vet J 2007, 39(5):446-450.
33. Paillot R., Prowse L., Donald C., Medcalf E., Montesso F., Bryant N., et al. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding. Vet Immunol Immunopathol 2010, 136(3-4):272-283.
34. Crouch C.F., Daly J., Henley W., Hannant D., Wilkins J., Francis M.J. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Vet Immunol Immunopathol 2005, 108(3-4):345-355. 15.
35. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 2005, 156(12):367-371.
36. Gildea S., Arkins S., Walsh C., Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt horses - a randomised blind study. Vaccine 2011, 29(22):3917-3922. 17.
37. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001, 211(2):143-153.
38. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000, 19(9-10):1180-1187.
39. Evans T.G., Kallas E.G., Campbell M., Andrews J., Schwartz D., Keefer M., et al. Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production. Immunol Lett 2001, 77(1):7-15.
40. Gorse G.J., Patel G.B., Mandava M.D., Arbuckle J.A., Doyle T.M., Belshe R.B. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120. Vaccine 2001, 19(13-14):1806-1819.
41. El Garch H., Minke J.M., Rehder J., Richard S., Edlund Toulemonde C., Dinic S., et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol 2008, 123(3-4):230-239.
42. Hannant D., Jessett D.M., O'Neill T., Livesay G.J., Mumford J.A. Cellular immune responses stimulated by inactivated virus vaccines and infection with equine influenza virus (H3N8). Equine Infectious Diseases VII. Proceedings of Seventh International Conference on Equine Infectious Diseases 1994, 169-174. R&W publications, Newmarket, UK. H. Nakajima, W. Plowright (Eds.).
43. Gotch F., McMichael A., Smith G., Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987, 165(2):408-416.
44. Kees U., Krammer P.H. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 1984, 159(2):365-377.
45. Townsend A.R., Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1984, 160(2):552-563.
46. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985, 82(6):1785-1789.
47. Sjolander A., van't Land B., Lovgren Bengtsson K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 1997, 177(1):69-76.
48. Sjolander A., Cox J.C., Barr I.G. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 1998, 64(6):713-723.
49. Sjolander A., Drane D., Maraskovsky E., Scheerlinck J.P., Suhrbier A., Tennent J., et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001, 19(17-19):2661-2665.
50. Onmaz A.C. Immunologic and inflammatory reactions after safety trial in horses with Duvaxyn IE-T vaccine. J Fac Vet Med Univ Erciyes 2007, 4(1):17-28.
51. Gelder C.M., Lambkin R., Hart K.W., Fleming D., Williams O.M., Bunce M., et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002, 185(1):114-117.
52. Lambkin R., Novelli P., Oxford J., Gelder C. Human genetics responses to influenza vaccination: clinical implications. Am J Pharmacogenom 2004, 4(5):293-298.
53. Edelman R. An overview of adjuvant use. Vaccine adjuvants, preparation methods and research protocols 2000, Humana Press, Inc, Totowa, New Jersey, USA. D.T. O'Hagan (Ed.).